AR021467A1 - A NON-HUMAN MAMMER WITH THE ARTIFICIALLY DONATED BRAIN, METHOD FOR TESTING COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS IN THE MAMMER AND USE OF COMPOSITIONS OR COMPOSITIONS. - Google Patents
A NON-HUMAN MAMMER WITH THE ARTIFICIALLY DONATED BRAIN, METHOD FOR TESTING COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS IN THE MAMMER AND USE OF COMPOSITIONS OR COMPOSITIONS.Info
- Publication number
- AR021467A1 AR021467A1 ARP990104225A ARP990104225A AR021467A1 AR 021467 A1 AR021467 A1 AR 021467A1 AR P990104225 A ARP990104225 A AR P990104225A AR P990104225 A ARP990104225 A AR P990104225A AR 021467 A1 AR021467 A1 AR 021467A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- compositions
- mammal
- brain
- mammer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un mamífero no humano con el cerebro artificialmente danado, método para ensayar compuestos o composiciones farmacéuticas en el mamífero y uso de loscompuestos o composiciones, donde el dano se hace a través del proceso de introducir una lesion en elcerebro de dicho mamífero no humano, donde dicha lesiones introducida en la amígdala de dicho mamífero no humano y donde dicho proceso comprende inyectar una citotoxina directamente dentro de la amígdala de unmamífero no humano pre-puber en el momento entre el nacimiento y el día que dicho mamífero se encuentra en la mitad entre el nacimiento y la pubertad; lacitotoxina causa una lesion por muerte de un numero de neuronas en la amígdala de dicho mamífero no humano pre-puber, y dicho proceso resulta en un danoartificial del cerebro del mamífero no humano el cual, cuando alcanza la pos-pubertad muestra un comportamiento anormal objetivamente medido en uno o másensayos de comportamientos estándares y donde dicho comportamiento anormal está asociado con desordenes en el sistema nervioso central, especialmentedesordenes psiquiátricos y más especialmente esquizofrenia, en seres humanos adultos, y donde dicho comportamiento difiere estadísticamente del comportamientocorrespondiente de mamíferos no humanos con lesiones falsas.A non-human mammal with the artificially damaged brain, method for testing pharmaceutical compounds or compositions in the mammal and use of the compounds or compositions, where the damage is done through the process of introducing an injury to the brain of said non-human mammal, where said lesions introduced into the tonsil of said non-human mammal and where said process comprises injecting a cytotoxin directly into the tonsil of a non-human pre-puber mammal at the time between birth and the day that said mammal is in the middle between birth and puberty; Lacitotoxin causes an injury by death of a number of neurons in the tonsil of said pre-puber non-human mammal, and said process results in a non-human brain damage of the non-human mammal which, when it reaches post-puberty, exhibits objectively abnormal behavior measured in one or more tests of standard behaviors and where said abnormal behavior is associated with disorders in the central nervous system, especially psychiatric disorders and more especially schizophrenia, in adult humans, and where such behavior differs statistically from the corresponding behavior of non-human mammals with false lesions .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98202873 | 1998-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021467A1 true AR021467A1 (en) | 2002-07-24 |
Family
ID=8234066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104225A AR021467A1 (en) | 1998-08-27 | 1999-08-24 | A NON-HUMAN MAMMER WITH THE ARTIFICIALLY DONATED BRAIN, METHOD FOR TESTING COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS IN THE MAMMER AND USE OF COMPOSITIONS OR COMPOSITIONS. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR021467A1 (en) |
| AU (1) | AU5740399A (en) |
| WO (1) | WO2000011943A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2234216C2 (en) * | 2000-10-10 | 2004-08-20 | Джапэн Эз Репрезентед Бай Президент Оф Ниигата Юниверсити | Method for obtaining an animal with stable sensomotor and behavioral disorders (variants) and application of transgenic animal according to epidermal growth factor as a model with stable sensomotor and behavioral disorders (variants) |
| US7902421B2 (en) | 2003-03-03 | 2011-03-08 | London Health Sciences Centre Research Inc. | Animal model for schizophrenia |
| FR2936527B1 (en) * | 2008-09-29 | 2025-03-28 | Univ Nancy 1 Henri Poincare | NON-HUMAN ANIMALS PRESENTING PSYCHIATRIC DISORDERS, METHOD FOR THEIR OBTAINMENT AND THEIR USE FOR SCREENING MEDICINES |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4004573A1 (en) * | 1989-02-17 | 1990-08-23 | Tanabe Seiyaku Co | NEW TRIAL AND HIS PRODUCTION |
| US5549884A (en) * | 1992-10-28 | 1996-08-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rat or mouse exhibiting behaviors associated with human schizophrenia |
-
1999
- 1999-08-24 AR ARP990104225A patent/AR021467A1/en unknown
- 1999-08-25 AU AU57403/99A patent/AU5740399A/en not_active Abandoned
- 1999-08-25 WO PCT/EP1999/006220 patent/WO2000011943A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5740399A (en) | 2000-03-21 |
| WO2000011943A1 (en) | 2000-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Benamer et al. | Myelination of parvalbumin interneurons shapes the function of cortical sensory inhibitory circuits | |
| Chen et al. | Repeated binge drinking increases perineuronal nets in the insular cortex | |
| Füzesi et al. | Hypothalamic CRH neurons orchestrate complex behaviours after stress | |
| Ligon et al. | Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons | |
| Jiang et al. | CRHCeA→ VTA inputs inhibit the positive ensembles to induce negative effect of opiate withdrawal | |
| Babaev et al. | Neuroligin 2 deletion alters inhibitory synapse function and anxiety-associated neuronal activation in the amygdala | |
| Clark et al. | Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact | |
| Ujvári et al. | Neurodegeneration in the centrally-projecting Edinger–Westphal nucleus contributes to the non-motor symptoms of Parkinson’s disease in the rat | |
| Leniger et al. | Clinical characteristics of patients with comorbidity of migraine and epilepsy | |
| Nie et al. | 2, 3, 7, 8‐Tetrachlorodibenzo‐p‐dioxin induces premature senescence of astrocytes via WNT/β‐catenin signaling and ROS production | |
| Paylor et al. | Impaired cognitive function after perineuronal net degradation in the medial prefrontal cortex | |
| Sajic et al. | High dietary fat consumption impairs axonal mitochondrial function in vivo | |
| Akman et al. | Early life status epilepticus and stress have distinct and sex‐specific effects on learning, subsequent seizure outcomes, including anticonvulsant response to phenobarbital | |
| CR7568A (en) | METHODS TO TREAT GASTROINTESTINAL AND GENITOURINARY PAIN DISORDERS THROUGH VINLAFAXINE AND ITS DERIVATIVES | |
| AR021467A1 (en) | A NON-HUMAN MAMMER WITH THE ARTIFICIALLY DONATED BRAIN, METHOD FOR TESTING COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS IN THE MAMMER AND USE OF COMPOSITIONS OR COMPOSITIONS. | |
| Chen et al. | Quetiapine modulates histone methylation status in oligodendroglia and rescues adolescent behavioral alterations of socially isolated mice | |
| Park et al. | Effects of chronic scopolamine treatment on cognitive impairments and myelin basic protein expression in the mouse hippocampus | |
| Takano et al. | Deciphering migraine | |
| Li et al. | Aurora B prevents aneuploidy via MAD2 during the first mitotic cleavage in oxidatively damaged embryos | |
| Jorda et al. | Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium | |
| Yu et al. | Strain hypothesis and additional evidence of the GluN3A deficiency‐mediated pathogenesis of Alzheimer's disease | |
| Xing et al. | TFEB ameliorates DEHP‐induced neurotoxicity by activating GAL3/TRIM16 axis dependent lysophagy and alleviating lysosomal dysfunction | |
| Kunkhyen et al. | Cell type-and layer-specific plasticity of olfactory bulb interneurons following olfactory sensory neuron ablation | |
| Yu et al. | Developing of focal ischemia in the hippocampus or the amygdala reveals a regional compensation rule for fear memory acquisition | |
| Mehri et al. | Rivastigmine ameliorates botulinum-induced hippocampal damage and spatial memory impairment in male rats |